Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.
about
Genetic Polymorphisms of Glutathione S-Transferase P1 (GSTP1) and the Incidence of Anti-Tuberculosis Drug-Induced HepatotoxicityRifampicin-Induced Concomitant Renal Injury and Hepatitis.Gender-Dimorphic Impact of PXR Genotype and Haplotype on Hepatotoxicity During Antituberculosis TreatmentIs the Prophylactic Use of Hepatoprotectants Necessary in Anti-Tuberculosis Treatment?Hepatobiliary Quiz Answers - 18 (2016).First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors.Prevalence of hepatitis C virus and human immunodeficiency virus in a group of patients newly diagnosed with active tuberculosis in Porto Alegre, Southern Brazil.Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress.Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice.Nucleoside analogs and tuberculosis: new weapons against an old enemy.Hepatotoxicity mechanisms of isoniazid: A mini-review.Complex Approach to Xenobiotics Hepatotoxicity Testing using a Microfluidic System.Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.Development of a biocompatible nanodelivery system for tuberculosis drugs based on isoniazid-Mg/Al layered double hydroxide.Involvement of protoporphyrin IX accumulation in the pathogenesis of isoniazid/rifampicin-induced liver injury: the prevention of curcumin.Ginger for Prevention of Antituberculosis-induced Gastrointestinal Adverse Reactions Including Hepatotoxicity: A Randomized Pilot Clinical Trial.Effect of Prophylactic Use of Silymarin on Anti-tuberculosis Drugs Induced Hepatotoxicity.Hepatobiliary quiz-6 (2013).Bypassing the compromised mitochondrial electron transport with methylene blue alleviates efavirenz/isoniazid-induced oxidant stress and mitochondria-mediated cell death in mouse hepatocytes.A Community Perspective on the Inclusion of Pregnant Women in Tuberculosis Drug Trials.PharmGKB summary: isoniazid pathway, pharmacokinetics.Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: a randomized, clinical trial.Oxidative stress-mediated developmental toxicity induced by isoniazide in zebrafish embryos and larvae.Dysregulation of NRF2 in Cancer: from Molecular Mechanisms to Therapeutic Opportunities.Association of Antituberculosis Treatment and Lower Risk of Hyperlipidemia in Taiwanese Patients: A Population-Based Case-Control Study.Panomics for Precision Medicine.Prediction of metabolites of epoxidation reaction in MetaTox.Antituberculosis Drug-Induced Adverse Events in the Liver, Kidneys, and Blood: Clinical Profiles and Pharmacogenetic Predictors.The efficacy of latent tuberculosis treatment for immunocompetent uveitis patients with a positive T-SPOT.TB test: 6-year experience in a tuberculosis endemic region.Clinical relevance of LINC00152 and its variants in western Chinese tuberculosis patients.TLR1 polymorphisms are significantly associated with the occurrence, presentation and drug-adverse reactions of tuberculosis in Western Chinese adults.From the Cover: Characterization of Isoniazid-Specific T-Cell Clones in Patients with anti-Tuberculosis Drug-Related Liver and Skin Injury.Investigating the CYP2E1 Potential Role in the Mechanisms Behind INH/LPS-Induced Hepatotoxicity.Involvement of methylation of MicroRNA-122, -125b and -106b in regulation of Cyclin G1, CAT-1 and STAT3 target genes in isoniazid-induced liver injury.RepTB: a gene ontology based drug repurposing approach for tuberculosis.Oxidative Stress and First-Line Antituberculosis Drug-Induced Hepatotoxicity.The effect of ageing on isoniazid pharmacokinetics and hepatotoxicity in Fischer 344 rats.Laboratory confirmation of Buruli ulcer cases in Ghana, 2008-2016.Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment.Adjunctive dexamethasone for the treatment of HIV-infected adults with tuberculous meningitis (ACT HIV): Study protocol for a randomised controlled trial
P2860
Q28550148-E9FB8815-8B75-4446-A928-E4A0152BBC5AQ33436350-AEDC9688-673D-4CEB-B46C-4172B63B5064Q36194503-B3244078-940B-4B7F-B5B7-755CC8284E13Q36368104-C6B6A1FD-13D2-4BAA-B96B-1A72A45AB5D4Q37131606-B4E07531-2D6C-47AD-898E-3744C4C97071Q37666631-DDCF0524-353F-4BC1-8DFE-6ECE0A4814DEQ37705730-4D2E8AD3-C968-4BA1-93DB-94C21B77513CQ38208324-C64E3197-3FD3-4B62-9280-D50698CCC58EQ38391340-9D34E16B-31CE-43D7-AAA6-3F2C756B7647Q38397331-06E77206-AC86-4A1A-8F56-D65331AAE685Q38533596-6D7B86F8-177E-4DF3-AE82-94CB642AB700Q38766386-1FDBA88D-B3AF-4E2E-9173-D918B5F0EF15Q38851516-A1B14FD4-F85C-4997-BC06-84BF1C3D4DCCQ38945902-6AAC8341-9E2C-4869-80AF-DA42E25377F9Q39001465-E520D79C-1E52-4AC0-823F-1FC89EEE8AE2Q40765560-005268D8-A0EB-43DF-877A-ACF6A3B11677Q41124277-EB60741E-7F61-475E-8CD0-FDC1D01A83E1Q41258370-C0A71BA4-00A8-4C61-8EB9-E67CDFEC7F0CQ41626712-87542D7C-83FA-4E32-B379-283661C9BB4BQ41920085-8D27222A-4D25-468C-8FD1-8D212A59861DQ42090708-87516011-FA70-485D-A353-166D58C367D4Q42249947-58191220-D774-4B5C-AF1A-9056601CBBADQ46425509-D78DA4A3-8AF1-4F46-9A3F-93B12BE5442BQ47108372-1FADA2C6-DA1F-49AF-B002-66FFB170DABFQ47221266-85081C3D-7FC8-4DF9-8D8E-F71F3A6E365EQ47348974-BE92FD9C-5BB5-4C2A-A51B-034B65FF3F61Q47603570-E5D1E111-B729-4970-A9D9-3860AE64FFF0Q47715776-9481F3AD-A6D2-4EA9-A93A-1EE242DCBECBQ48290090-A0F5E271-C2BC-4FA4-AD83-381FFD0A62AFQ49294587-A39AAA28-4B38-4412-A0B9-C7A0FAFB3A1BQ49345526-3B20BF25-C6AA-422A-9A09-7C8736B83687Q51427499-30034E4B-9C95-480F-BCF0-301729E7C86DQ51736892-2ABCE85F-383B-4E67-BAAF-0BEF3F6013E2Q52725685-F8FCE0B6-C962-47E5-9132-549820520675Q54203363-A3A5C534-4C3D-4DD5-92B0-8D71692F6117Q54203690-E5E905D8-4220-4091-8BA5-E5B98E61133FQ55022756-C42502B3-7A0F-46F4-AE74-284B6E6AE9C0Q55365530-BC1A0468-35F7-42E1-9BC7-4E6F539BAE8EQ55517833-D7618915-75B8-4187-B330-6B3392E8C24DQ57496816-3089E860-D9EA-4F06-B307-4AFA81EDBAFD
P2860
Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 December 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.
@en
Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.
@nl
type
label
Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.
@en
Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.
@nl
prefLabel
Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.
@en
Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.
@nl
P2860
P1476
Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.
@en
P2093
Vidyasagar Ramappa
P2860
P356
10.1016/J.JCEH.2012.12.001
P577
2012-12-20T00:00:00Z